TRABECULECTOMY IN PSEUDOPHAKIC PATIENTS - POSTOPERATIVE 5-FLUOROURACIL VERSUS INTRAOPERATIVE MITOMYCIN-C ANTIPROLIFERATIVE THERAPY

Trabeculectomy outcome in pseudophakic glaucoma patients treated with mitomycin C (MMC) or 5-fluorouracil (5-FU) was analyzed retrospectivel y in 46 cases (46 eyes). Thirty patients received intraoperative MMC; 16, 5-FU. There were no significant differences between the two groups in terms of preoperative data (demographics, number of previous filte ring procedures, visual acuity, and intraocular pressure [IOP]). After a mean follow up of 13.4 +/- 8.1 and 11.5 +/- 5.8 months for the 5-FU and MMC groups, respectively, 12 5-FU eyes (75%) and 21 MMC eyes (70% ) were deemed at least qualified successes (IOP less-than-or-equal-to 21 mm Hg with or without antiglaucoma medications). Six (37.5%) of the 5-FU eyes and 13 (43.3%) of the MMC eyes were complete successes (IOP less-than-or-equal-to 21 mm Hg without antiglaucoma medications). The re were no significant differences between the two groups in terms of duration of follow up, number of qualified successes, and number of co mplete successes (P = .35, .9, and .7, respectively). Nor were there a ny significant differences in the mean final IOPs and visual acuities. Excluding transient corneal effects associated with 5-FU therapy, the re were no significant differences in the frequency of postoperative c omplications. These results suggest that 5-FU and MMC antiproliferativ e therapy are associated with similar short-term success rates and pos toperative complications.